The clinical characteristics of breast cancer or ovarian cancer were similar between carriers of RAD51C and carriers of RAD51D. Breast cancer cases were enriched for ER-negative phenotype (52.8%), an aggressive tumor type lacking targeted therapies apart from the use of PARP inhibitors for patients with germline BRCA1/2 PVs. This evidence concerns the gene BRCA1 and ovarian carcinoma.